T细胞疗法-话题@MedSci

#T细胞疗法#

95篇内容 | 3222人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1478056, encodeId=b64114e80569d, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=NEJM：BCMA靶向CAR-T细胞疗法Idecabtagene Vicleucel（Ide-cel）取得积极结果, objectType=article, longId=207624, objectId=eba320e6248f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eba320e6248f, replyNumber=0, likeNumber=79, createdTime=2021-02-27, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eba320e6248f, moduleTitle=NEJM：BCMA靶向CAR-T细胞疗法Idecabtagene Vicleucel（Ide-cel）取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eba320e6248f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478055, encodeId=498a14e805562, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=美国FDA宣布：全球第4款CAR-T细胞疗法获批上市，治疗复发性或难治性大B细胞淋巴瘤，安全性更高！, objectType=article, longId=206908, objectId=2d6520690891, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d6520690891, replyNumber=0, likeNumber=78, createdTime=2021-02-09, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d6520690891, moduleTitle=美国FDA宣布：全球第4款CAR-T细胞疗法获批上市，治疗复发性或难治性大B细胞淋巴瘤，安全性更高！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d6520690891)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478054, encodeId=e25614e805490, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Blood：皮质醇用的越多，采用CAR T细胞疗法治疗的大B细胞淋巴瘤患者的预后越差！, objectType=article, longId=206779, objectId=c005206e79a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c005206e79a5, replyNumber=0, likeNumber=87, createdTime=2021-02-06, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c005206e79a5, moduleTitle=Blood：皮质醇用的越多，采用CAR T细胞疗法治疗的大B细胞淋巴瘤患者的预后越差！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c005206e79a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478053, encodeId=cd0a14e805322, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Lenzilumab预防或治疗与CAR-T细胞疗法相关细胞因子风暴和神经毒性, objectType=article, longId=204991, objectId=a8c8204991ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8c8204991ff, replyNumber=0, likeNumber=85, createdTime=2020-12-31, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8c8204991ff, moduleTitle=Lenzilumab预防或治疗与CAR-T细胞疗法相关细胞因子风暴和神经毒性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8c8204991ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478052, encodeId=46d414e8052ce, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Clin Cancer Res：JAK1抑制剂Itacitinib可有效预防CAR T细胞疗法引发的细胞因子释放综合征, objectType=article, longId=204517, objectId=6bae20451ef6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6bae20451ef6, replyNumber=0, likeNumber=68, createdTime=2020-12-16, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6bae20451ef6, moduleTitle=Clin Cancer Res：JAK1抑制剂Itacitinib可有效预防CAR T细胞疗法引发的细胞因子释放综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6bae20451ef6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478051, encodeId=463f14e80516a, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=CRISPR编辑的CAR-T细胞疗法增强了对抗血癌的能力, objectType=article, longId=204328, objectId=6b2e20432812, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b2e20432812, replyNumber=0, likeNumber=72, createdTime=2020-12-10, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b2e20432812, moduleTitle=CRISPR编辑的CAR-T细胞疗法增强了对抗血癌的能力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b2e20432812)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478050, encodeId=382b14e8050e4, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Nature Cancer：iNKT细胞疗法“新兵”——双特异性抗体, objectType=article, longId=203619, objectId=306220361914, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=306220361914, replyNumber=0, likeNumber=77, createdTime=2020-11-23, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=306220361914, moduleTitle=Nature Cancer：iNKT细胞疗法“新兵”——双特异性抗体, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=306220361914)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478049, encodeId=bd9d14e80498d, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=CAR-T细胞疗法MB-102治疗BPDCN、AML、hrMDS：即将开展多中心I/II期临床试验, objectType=article, longId=201543, objectId=a72820154315, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a72820154315, replyNumber=0, likeNumber=103, createdTime=2020-10-04, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a72820154315, moduleTitle=CAR-T细胞疗法MB-102治疗BPDCN、AML、hrMDS：即将开展多中心I/II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a72820154315)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478048, encodeId=23e514e804800, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=李懿点评 | TCR-T细胞疗法，三大障碍有待突破, objectType=article, longId=200496, objectId=598f20049681, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=598f20049681, replyNumber=0, likeNumber=96, createdTime=2020-09-11, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=598f20049681, moduleTitle=李懿点评 | TCR-T细胞疗法，三大障碍有待突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=598f20049681)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478047, encodeId=a0dd14e804745, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Nat Med ：新型双CAR-T细胞疗法，快速清除体内HIV病毒，持久保护, objectType=article, longId=200191, objectId=d92e20019135, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d92e20019135, replyNumber=0, likeNumber=100, createdTime=2020-09-05, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d92e20019135, moduleTitle=Nat Med ：新型双CAR-T细胞疗法，快速清除体内HIV病毒，持久保护, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d92e20019135)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478046, encodeId=364c14e8046a6, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=同种异体CAR-T细胞疗法治疗白血病，获得FDA的快速通道指定, objectType=article, longId=199754, objectId=3106199e5420, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3106199e5420, replyNumber=0, likeNumber=59, createdTime=2020-08-22, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3106199e5420, moduleTitle=同种异体CAR-T细胞疗法治疗白血病，获得FDA的快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3106199e5420)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478045, encodeId=083214e80451a, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=CAR-T细胞疗法Idecabtagene Vicleucel治疗复发难治多发性骨髓瘤：已提交BLA, objectType=article, longId=198425, objectId=61571984251d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61571984251d, replyNumber=0, likeNumber=62, createdTime=2020-08-01, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61571984251d, moduleTitle=CAR-T细胞疗法Idecabtagene Vicleucel治疗复发难治多发性骨髓瘤：已提交BLA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61571984251d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478044, encodeId=f39114e8044ff, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=如何治疗间皮素阳性晚期实体瘤？新型T细胞疗法TC-210有效性显著, objectType=article, longId=198174, objectId=d7451981e47c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7451981e47c, replyNumber=0, likeNumber=95, createdTime=2020-07-29, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7451981e47c, moduleTitle=如何治疗间皮素阳性晚期实体瘤？新型T细胞疗法TC-210有效性显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7451981e47c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478043, encodeId=e1ba14e804329, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=FDA批准CAR-T细胞疗法Tecartus治疗复发难治套细胞淋巴瘤, objectType=article, longId=198053, objectId=701319805312, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=701319805312, replyNumber=0, likeNumber=34, createdTime=2020-07-27, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=701319805312, moduleTitle=FDA批准CAR-T细胞疗法Tecartus治疗复发难治套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=701319805312)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478042, encodeId=57af14e80427e, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=**iPSC衍生的CAR-T细胞疗法：IND已获FDA批准, objectType=article, longId=197391, objectId=8b4a19e3919e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b4a19e3919e, replyNumber=0, likeNumber=93, createdTime=2020-07-13, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b4a19e3919e, moduleTitle=**iPSC衍生的CAR-T细胞疗法：IND已获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b4a19e3919e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478041, encodeId=a7aa14e80412c, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=CAR-T细胞疗法和双特异性抗体再发力：罗氏与信达生物签署20亿美元合作协议, objectType=article, longId=195728, objectId=ce9d195e287e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce9d195e287e, replyNumber=0, likeNumber=90, createdTime=2020-06-13, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce9d195e287e, moduleTitle=CAR-T细胞疗法和双特异性抗体再发力：罗氏与信达生物签署20亿美元合作协议, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce9d195e287e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478040, encodeId=fdba14e8040ae, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=T细胞疗法DSG3-CAART获得FDA快速通道认证：用于治疗寻常型粘膜天疱疮, objectType=article, longId=193723, objectId=bd8a193e2301, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd8a193e2301, replyNumber=0, likeNumber=73, createdTime=2020-05-09, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd8a193e2301, moduleTitle=T细胞疗法DSG3-CAART获得FDA快速通道认证：用于治疗寻常型粘膜天疱疮, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd8a193e2301)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478039, encodeId=c25f14e80396c, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=欧盟EMA为T细胞疗法ADP-A2M4授予孤儿药指定，用于治疗软组织肉瘤, objectType=article, longId=193369, objectId=5b57193369b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b57193369b8, replyNumber=0, likeNumber=69, createdTime=2020-05-03, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b57193369b8, moduleTitle=欧盟EMA为T细胞疗法ADP-A2M4授予孤儿药指定，用于治疗软组织肉瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b57193369b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478038, encodeId=1e8e14e803804, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Triumvira与Lonza宣布合作开发T细胞疗法：自动化制造流程将推动该领域的进展, objectType=article, longId=190846, objectId=00b81908467c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00b81908467c, replyNumber=0, likeNumber=84, createdTime=2020-03-27, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00b81908467c, moduleTitle=Triumvira与Lonza宣布合作开发T细胞疗法：自动化制造流程将推动该领域的进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00b81908467c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478037, encodeId=096214e803719, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Nature Communication：CAR-T细胞疗法后复发怎么办？新型CAR-T疗法或提供帮助, objectType=article, longId=187730, objectId=1d2918e73091, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d2918e73091, replyNumber=0, likeNumber=63, createdTime=2020-02-10, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d2918e73091, moduleTitle=Nature Communication：CAR-T细胞疗法后复发怎么办？新型CAR-T疗法或提供帮助, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d2918e73091)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

T细胞疗法

2020-05-29

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

NEJM：BCMA靶向CAR-T细胞疗法Idecabtagene Vicleucel（Ide-cel）取得积极结果

2021-02-27

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

美国FDA宣布：全球第4款CAR-T细胞疗法获批上市，治疗复发性或难治性大B细胞淋巴瘤，安全性更高！

2021-02-09

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Blood：皮质醇用的越多，采用CAR T细胞疗法治疗的大B细胞淋巴瘤患者的预后越差！

2021-02-06

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Lenzilumab预防或治疗与CAR-T细胞疗法相关细胞因子风暴和神经毒性

2020-12-31

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Clin Cancer Res：JAK1抑制剂Itacitinib可有效预防CAR T细胞疗法引发的细胞因子释放综合征

2020-12-16

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

CRISPR编辑的CAR-T细胞疗法增强了对抗血癌的能力

2020-12-10

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Nature Cancer：iNKT细胞疗法“新兵”——双特异性抗体

2020-11-23

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

CAR-T细胞疗法MB-102治疗BPDCN、AML、hrMDS：即将开展多中心I/II期临床试验

2020-10-04

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

李懿点评 | TCR-T细胞疗法，三大障碍有待突破

2020-09-11

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Nat Med ：新型双CAR-T细胞疗法，快速清除体内HIV病毒，持久保护

2020-09-05

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

同种异体CAR-T细胞疗法治疗白血病，获得FDA的快速通道指定

2020-08-22

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

CAR-T细胞疗法Idecabtagene Vicleucel治疗复发难治多发性骨髓瘤：已提交BLA

2020-08-01

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

如何治疗间皮素阳性晚期实体瘤？新型T细胞疗法TC-210有效性显著

2020-07-29

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

FDA批准CAR-T细胞疗法Tecartus治疗复发难治套细胞淋巴瘤

2020-07-27

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

**iPSC衍生的CAR-T细胞疗法：IND已获FDA批准

2020-07-13

heli0118 (审核中...)

前往app查看评论内容

#T细胞疗法#

CAR-T细胞疗法和双特异性抗体再发力：罗氏与信达生物签署20亿美元合作协议

2020-06-13

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

T细胞疗法DSG3-CAART获得FDA快速通道认证：用于治疗寻常型粘膜天疱疮

2020-05-09

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

欧盟EMA为T细胞疗法ADP-A2M4授予孤儿药指定，用于治疗软组织肉瘤

2020-05-03

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Triumvira与Lonza宣布合作开发T细胞疗法：自动化制造流程将推动该领域的进展

2020-03-27

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Nature Communication：CAR-T细胞疗法后复发怎么办？新型CAR-T疗法或提供帮助

2020-02-10

科室
- - 订阅+
  - 更多科室
工具
服务